Paxlovid ke moriana oa lipatlisiso o sebelisetsoang ho phekola COVID-19 e bobebe ho isa ho e itekanetseng ho batho ba baholo le bana ba lilemo tse 12 ho ea holimo ba boima ba lik'hilograma tse 88 (40 kg) ka liphetho tse ntle tsa tlhahlobo e tobileng ea vaerase ea SARS-CoV-2, le ba kotsing e kholo ea ho fetela ho COVID-19 e matla, ho kenyeletsoa ho kena sepetlele kapa lefu. Paxlovid ke ea lipatlisiso hobane e ntse e ithutoa. Ho na le lintlha tse fokolang mabapi le polokeho le katleho ea ho sebelisa Paxlovid ho alafa batho ba nang le COVID-19 e bobebe ho isa ho e itekanetseng.
FDA e lumelletse ts'ebeliso ea tšohanyetso ea Paxlovid bakeng sa kalafo ea COVID-19 e bobebe ho isa ho e itekanetseng ho batho ba baholo le bana [ba lilemo li 12 le ho feta ba boima ba liponto tse 88 (40 kg)] ka tlhahlobo e ntle bakeng sa vaerase eo. e baka COVID-19, mme ba kotsing e kholo ea ho fetela ho COVID-19 e matla, ho kenyeletsoa ho kena sepetlele kapa lefu, tlasa EUA.

Paxlovid ha se moriana o amohetsoeng ke FDA United States. Bua le mofani oa tlhokomelo ea bophelo mabapi le likhetho tsa hau kapa haeba u na le lipotso. Ke khetho ea hau ho nka Paxlovid.

Paxlovid e na le meriana e 'meli: nirmatrelvir le ritonavir.

Nirmatrelvir [PF-07321332] ke SARS-CoV-2 main protease (Mpro) inhibitor (eo hape e tsejoang e le SARS-CoV2 3CL protease inhibitor) e sebetsang ka ho thibela ho ikatisa ha vaerase methating ea pele ea lefu lena ho thibela tsoelo-pele ho COVID- 19.

Ritonavir e tsamaellana le nirmatrelvir ho thusa ho liehisa metabolism ea eona hore e lule e le mafolofolo 'meleng nako e telele maemong a holimo ho thusa ho loants'a vaerase.